Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2347${count})

  • Research Grant, 2022
    Shoring Up a Medical Chemistry Approach to Treating Parkinson’s Disease: The Bridge Initiative

    Study Rationale: The proteins parkin and GCase show a strong genetic link to Parkinson’s disease (PD) and are key players of biological pathways often disrupted in the disorder. This connection makes...

  • Proof-of-Concept Testing of PD Therapeutics, 2022
    Using Data from the LEAPS Project to Improve the Accuracy of Assays that Measure Alpha-synuclein

    Study Rationale: The scientific and clinical research community working on Parkinson’s disease (PD) is in need of biomarkers to facilitate the monitoring of disease progression and efficacy of...

  • Target Advancement Program, 2022
    Enhancing N-glycosylation of Glucocerebrosidase and other Lysosomal Enzymes as a Disease Modifying Therapy for Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is an age-related neurological movement disorder characterized by the abnormal aggregation of a protein called α-synuclein (α-syn) in the brain. Normally...

  • Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022
    Identification and Quantification of Parkinson’s Disease Progression Using Digital Measures from a Wrist-worn Wearable Device - a Retrospective Study

    Study Rationale: The combination of digital measures and machine learning (ML) holds great promise for improving critical aspects of Parkinson’s disease (PD) care, practice and research. Earlier PD...

  • Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022
    Project Title: Clinical Development of PDM608, a Potential Neuroprotective and Anti-inflammatory Long-acting Biologic for Parkinson’s Disease

    Study Rationale: Targeting neuroinflammation by increasing T regulatory cell numbers is a promising strategy for treating Parkinson’s disease. We propose a Phase 1 trial in non-PD volunteers for our...

  • Spring 2022 RFA: Target Advancement Program - Target Validation, 2022
    Validating BMPs as Novel Drug Candidates for Parkinson’s Disease

    Study Rationale: Neurotrophic factors are prime candidates for the development of disease-modifying therapies, based on their properties to restore and maintain the functional integrity of neurons...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.